Saccharomyces Boulardii IgA

Some people's immune systems make a lasting ASCA antibody response to yeast-like sugars. In stored blood, this pattern has sometimes appeared years before a Crohn's diagnosis.

This test measures one part of that response: IgA-class ASCA in blood. It won't diagnose Crohn's on its own, but a positive result can add weight when symptoms, family history, stool inflammation, or imaging already point that way. In people who already have inflammatory bowel disease, it can sometimes mark a more demanding course.

What This Antibody Reflects

The test measures IgA antibodies against Saccharomyces cerevisiae, the yeast species used in bread and beer. IgA is a class of antibody your body uses heavily at surfaces like the gut lining. Labs usually call this family of tests ASCA: anti-Saccharomyces cerevisiae antibodies.

Most ASCA research measures serum IgA, serum IgG, or both. This page is about IgA, so findings from IgG or combined ASCA studies are related evidence, not the exact same measurement.

Saccharomyces boulardii is the probiotic yeast sold in capsules. It is usually classified as a variety or strain of S. cerevisiae. The blood test is not a probiotic test. It measures whether your immune system is making antibodies to yeast-like sugar patterns used in ASCA assays.

A high level means your immune system recognizes yeast-like sugar patterns in a sustained way. It may reflect fungal exposure, gut immune tendency, and sometimes gut barrier leakiness. It is not proof that yeast is harming you or that yeast sugars simply leaked through the gut wall.

Crohn's Disease

This is where ASCA matters most. In people who later developed inflammatory bowel disease, serum ASCA and other markers were present years before diagnosis. The signal was stronger for future Crohn's than for future ulcerative colitis.

The antibody also helps separate Crohn's from its main lookalike. ASCA is much more common in Crohn's than in ulcerative colitis, especially when pANCA is absent. pANCA is a second antibody pattern more often seen in ulcerative colitis. Together, the pattern can help when the diagnosis is unclear.

It is an adjunct. Colonoscopy, biopsy, stool testing, and imaging still carry the diagnosis.

ASCA positivity or higher titers also track with a tougher Crohn's pattern in several cohorts. They have been linked to small-bowel disease, scarring or tunneling behavior, and in children to more severe or extensive disease. The link to surgery is less consistent across studies.

A positive result carries weight, but a negative one does not clear you. Many people with Crohn's never test positive, so this antibody rules the disease in more than it rules it out.

Ulcerative Colitis

For predicting who will develop ulcerative colitis, this antibody is weak. The prediagnosis signature that worked for Crohn's did not work well for ulcerative colitis.

Among people who already have ulcerative colitis, high ASCA IgA may mark a subgroup that needs heavier treatment. In one Hungarian cohort followed for a median of more than 11 years, ASCA IgA positivity predicted a nearly threefold higher chance of long-term immunosuppressant treatment, most often azathioprine.

That can look backward at first: a Crohn's-linked antibody showing up inside ulcerative colitis. The cleaner way to read it is as a gut-immune phenotype marker, not a yes-or-no disease test. It reflects one kind of microbial antibody response that can matter after disease is already present.

Severe Alcohol-Related Hepatitis

Related serum ASCA testing has also been studied in severe alcohol-related hepatitis. This is not the same as using an IgA-only ASCA test for inflammatory bowel disease, so it should be treated as nearby evidence, not direct interpretation for this test.

In hospitalized adults with severe alcohol-related hepatitis, higher serum ASCA was linked to worse 90- and 180-day survival. The association remained after accounting for infection, steroid treatment, and liver severity. This comes from one cohort.

Across these different settings, the size of the risk shift is worth seeing side by side.

Sources, in order: Desir et al. for pediatric Crohn's; Kovacs et al. for ulcerative colitis; Lang et al. for alcohol-related hepatitis.

The same antibody carries different weight depending on your situation. If you already have inflammatory bowel disease, a high level is a reason to watch for a more demanding course and stay on top of monitoring, not a signal to change treatment by itself.

One Reading, Held Over Time

Unlike markers that swing with your last meal or workout, ASCA status is fairly stable. Some levels can drift, but positive-versus-negative status often changes little over time and may stay stable after bowel surgery.

That has two consequences. A clear positive does not need a year of trending to matter. Repeating can confirm an unexpected or borderline result, but long-term monitoring usually belongs to symptoms, stool calprotectin, CRP, and other markers that respond to current inflammation.

What a Positive Result Should Make You Do

A positive result is a prompt to widen the workup, not to panic. If you also have gut symptoms like ongoing diarrhea, abdominal pain, blood in the stool, or unexplained weight loss, check stool and blood inflammation markers and bring the pattern to a gastroenterologist. Colonoscopy or small-bowel imaging may be needed if the full picture points to inflammatory bowel disease.

The antibody rarely stands alone. It is usually read alongside pANCA and stool calprotectin. Calprotectin shows whether the gut is inflamed now.

If you feel well and the result is positive, the move is awareness, not treatment. Note it, especially if Crohn's or colitis runs in your family. New gut symptoms should not be waved away.

When Results Can Be Misleading

• IgA deficiency: this test detects IgA-class antibodies, so if your body makes little or no IgA, the result can read falsely low even when your gut immune system is reacting. A total IgA test checks for this.
• A negative doesn't clear you: the test misses many people who actually have Crohn's, so a normal result is reassuring but not conclusive.
• Dietary yeast and probiotics: one meal is unlikely to change antibody levels, and studies have not shown that ordinary yeast intake reliably drives ASCA. In people who are already ASCA positive, dietary yeast may still affect gut symptoms even when it does not move the antibody number. Probiotic use has not been proven to change the result.
• Other fungi can cross-react: ASCA assays use S. cerevisiae mannan, but Candida can share similar sugar patterns, so a positive result is not proof that S. cerevisiae itself is the trigger.
• Lab-to-lab differences: there is no single standardized cutoff, so results from different labs are not directly comparable, and a borderline number should be confirmed before you act on it.